Previous 10 | Next 10 |
Genmab (GMAB) said an arbitral tribunal has ruled in favor of Johnson & Johnson's (NYSE:JNJ) Janssen Biotech in both matters related to royalty payments under their license agreement related to cancer drug daratumumab. On the first issue, the tribunal determined by maj...
Halozyme Therapeutics (NASDAQ:HALO) has granted Chugai a license to its ENHANZE drug delivery technology for use in an undisclosed target. The ENHANZE technology is based on the recombinant human hyaluronidase PH20 enzyme (rHuPH20). Terms of the collaboration and license agreement call f...
Halozyme Therapeutics, Inc. and Chugai Pharmaceutical Enter Global Collaboration and License Agreement for ENHANZE® Technology PR Newswire SAN DIEGO , March 24, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced a global ...
Positive Topline Results Announced from ADAPT-SC Study Evaluating Subcutaneous Efgartigimod Using ENHANZE® Drug Delivery Technology for Generalized Myasthenia Gravis PR Newswire - Study met primary endpoint, demonstrating noninferior total IgG reduction at day 29 ...
Halozyme Appoints Moni Miyashita to Board of Directors PR Newswire SAN DIEGO , March 15, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the appointment of Moni Miyashita to its board of directors. Ms. Miyashita is an a...
I was drawn to Halozyme due to its business model that is devoid of in-house drug development. Halozyme reformulates many blockbuster drugs that provided them with significant milestones and royalty. What is more, the impressive number of partners diversifies their revenue sources and...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Halozyme Therapeutics, Inc. (HALO) Q4 2021 Earnings Conference Call February 22, 2022 4:30 P.M. ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer...
Halozyme Therapeutics press release (NASDAQ:HALO): Q4 Non-GAAP EPS of $0.42 beats by $0.01. Revenue of $102M (-16.2% Y/Y) beats by $2.31M. 2022 Revenue Guidance of $530 to $560 Million Representing 20-26% Growth over Reported 2021 Revenue. Recurring Revenue from Royalties in 2022 Expected to ...
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS -<span class="legendSpanClass">Reports Fourth Quarter Revenue of $102.0 million with GAAP Diluted Earnings per Share of $0.46 and Non-GAAP Diluted Earnings per Share of $0.42 -</span> -<span class="leg...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...